Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the environmental liabilities hidden in Ingevity’s 200-page 10-K or tracking resin cost swings across three segments can feel overwhelming. Ingevity’s specialty chemical operations—Performance Chemicals, Advanced Polymer Technologies, and activated-carbon-driven Performance Materials—create dense disclosures that analysts must sift through line by line.
Our platform turns that burden into clarity. Stock Titan delivers AI-powered summaries for every document, from the Ingevity annual report 10-K simplified to an Ingevity quarterly earnings report 10-Q filing. Need the latest Ingevity 8-K material events explained after a caprolactone plant outage? Want Ingevity Form 4 insider transactions real-time alerts before the market opens? We stream filings directly from EDGAR, tag key metrics such as segment EBITDA or remediation accruals, and answer natural questions like “understanding Ingevity SEC documents with AI.”
Here’s how professionals use the page:
- Monitor Ingevity insider trading Form 4 transactions and gauge executive confidence.
- Compare asphalt-additive margin trends with our Ingevity earnings report filing analysis.
- Review the Ingevity proxy statement executive compensation to align pay with performance.
Every filing—10-K, 10-Q, 8-K, DEF 14A, S-8, and more—is parsed, highlighted, and cross-linked. Whether you’re screening Ingevity executive stock transactions Form 4 or simply want Ingevity SEC filings explained simply, our real-time updates and expert context keep you ahead of the curve.
Ingevity Corp (NGVT) director Luis Fernandez-Moreno reported a sale and adjustments to his holdings tied to restricted stock units. On
The Form 4 was filed as an individual report and bears a signature submitted by an attorney-in-fact on behalf of Mr. Fernandez-Moreno on
Francis David Segal, a director of Ingevity Corp (NGVT), reported acquiring 414 vested deferred stock units on 10/01/2025 at a recorded price of $54.44 per share equivalent. These DSUs were elected in lieu of quarterly director fees and will convert into an equal number of common shares when Mr. Segal leaves board service under the company's Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this transaction, his reported beneficial ownership is 5,655 shares, held directly.
J. Kevin Willis, a director of Ingevity Corp (NGVT), reported a transaction dated 10/01/2025 in which he acquired 506 shares of Common Stock at a price of $54.44 per share. The Form 4 shows the shares represent vested deferred stock units that were elected in lieu of quarterly director fees and will convert into common shares upon his termination of board service under the company plans. After the reported transaction the filing shows the reporting person beneficially owned 8,300 shares directly. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Phillip J. Platt, SVP, Finance & CAO of Ingevity Corp (NGVT), reported an equity transaction tied to vested restricted stock units. On 08/11/2025 the company withheld 1,444 shares to satisfy tax-withholding obligations related to 2024 RSUs that vested on that date. The transaction is coded F and shows a withholding value of $52.20 per share. After the withholding, Mr. Platt directly beneficially owned 28,243 shares.
This was a routine tax-withholding action for vested equity rather than an open-market sale; the form was submitted by one reporting person and executed under a power of attorney.
Ingevity Corporation (NGVT) Form 144 reports that insider Stuart E. Woodcock Jr. intends to sell 3,700 common shares on 08/11/2025 through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $194,662.55. The filing lists the securities as restricted stock that vested under a registered plan with acquisition dates of 02/27/2017, 02/27/2018 and 02/26/2020, and records a recent separate sale on 08/05/2025 of 6,720 shares for $323,904.00. Outstanding shares are shown as 36,466,285, so the planned sale represents a very small fraction of total common stock.
The notice includes the seller’s representation that they do not possess undisclosed material adverse information. The document otherwise provides routine Rule 144 disclosure details: broker, share counts, acquisition type, and prior recent sales by the same person.
Ingevity Corporation (NGVT) – Form 4 Insider Filing: Senior Vice President, General Counsel & Secretary Ryan C. Fisher reported a transaction dated 7 July 2025. The filing shows a Code F transaction in which 169 shares of common stock were withheld by the company at a price of $45.34 per share to cover tax obligations arising from the vesting of 2024 restricted stock units (RSUs). After the withholding, Fisher’s direct ownership stands at 14,758 NGVT shares. No derivative securities activity was reported, and there were no open-market purchases or sales.
Because Code F transactions are non-discretionary, cashless, and executed solely for tax-withholding, they typically carry limited market signaling value. The ownership reduction equals roughly -1.1% of Fisher’s previously held shares, a de-minimis change that is unlikely to materially affect investor perception of insider sentiment or the company’s share supply.